Shots:
- The alliance will investigate the effectiveness of LPC-bound EPA/DHA in preventing cognitive decline linked to AD. Aker BioMarine will supply the research team with its krill-based LPC EPA/DHA product (Lysoveta)
- The team will evaluate the link between genetic variations in lipid metabolism & transport of EPA/DHA across the BBB using knock-in mice for human E4 (hAPOE4) or E3 (hAPOE3) genetic variants
- Aker BioMarine launches Lysoveta based on LPC-bound EPA/DHA from krill and is effective in increasing the concentration of DHA in the brain and improving cognition. The company plans to launch a product for human health in 2022
Click here to read full press release/ article | Ref: Aker BioMarine | Image: Aker BioMarine
The post Aker BioMarine Collaborate with Université de Sherbrooke Department of Medicine for Alzheimer’s Disease first appeared on PharmaShots.
